Company profile for Enterome

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer (OncoMimics™ peptides). Enterome’s pioneering approach to drug discovery is based on its unique ability to decode the interaction between the gut microbiome and the immune system. Enterome’s Mimicry drug discovery platform uses best-in-class biocomputational tools & bioassays to ide...
Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer (OncoMimics™ peptides). Enterome’s pioneering approach to drug discovery is based on its unique ability to decode the interaction between the gut microbiome and the immune system. Enterome’s Mimicry drug discovery platform uses best-in-class biocomputational tools & bioassays to identify novel therapeutics from its proprietary database of 20+ million full-length gut microbiome proteins. This platform is highly productive & has already generated multiple pipelines of transformative drug candidates.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
France
Address
Address
94/96 avenue Ledru-Rollin 75011 Paris
Telephone
Telephone
+33 (0)1 75 77 27 85
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/10/16/3167636/0/en/Enterome-receives-FDA-Fast-Track-designation-in-follicular-lymphoma-for-lead-OncoMimics-immunotherapy-EO2463.html

GLOBENEWSWIRE
16 Oct 2025

https://www.globenewswire.com/news-release/2025/06/23/3103112/0/en/Enterome-presents-positive-Phase-2-interim-results-in-relapsed-refractory-indolent-non-Hodgkin-lymphoma-after-EO2463-OncoMimics-immunotherapy-treatment-at-ICML.html

GLOBENEWSWIRE
23 Jun 2025

https://www.globenewswire.com/news-release/2025/06/12/3098067/0/en/Enterome-raises-19-million-to-fund-clinical-development-of-its-OncoMimics-immunotherapy-to-treat-Follicular-Lymphoma.html

GLOBENEWSWIRE
12 Jun 2025

https://www.globenewswire.com/news-release/2025/06/02/3091776/0/en/Enterome-to-present-positive-Phase-2-indolent-non-Hodgkin-lymphoma-data-for-its-OncoMimics-EO2463-at-ICML.html

GLOBENEWSWIRE
02 Jun 2025

https://www.globenewswire.com/news-release/2025/05/30/3090836/0/en/Enterome-presents-positive-Phase-1-2-MSS-pMMR-metastatic-colorectal-cancer-data-in-patients-treated-with-EO4010-OncoMimics-immunotherapy-plus-nivolumab-at-ASCO-2025.html

GLOBENEWSWIRE
30 May 2025

https://www.globenewswire.com/news-release/2024/12/11/2995198/0/en/Enterome-Presents-Encouraging-Initial-Clinical-Data-on-EO4010-in-Colorectal-Cancer-at-ESMO-IO-2024.html

GLOBENEWSWIRE
11 Dec 2024

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty